Glaxo Group Limited

Glaxosmithkline LLC

Glaxogrouplimited

Giovanna Tedesco

Fabrizio Micheli

Luca Tarsi

Silvia Terreni

Anna Maria Capelli

Dieter Hamprecht

Giorgio Bonanomi

Gabriella Gentile

Romano Di Fabio

Federica Damiani

Barbara Bertani

Alessandra Pasquarello

Luca Arista

Giovanni Gaviraghi

Daniele Andreotti

Paolo Dambruoso

Tino Rossi

Stefano Biondi

Anna Checchia

Domenica Antonia Pizzi

Aldo Feriani

Emiliangelo Ratti

Elettra Fazzolari

Francesca Cardullo

Gabriella Finizia

Paola Marzorati

Catia Seri

Dieter Wolfgang Hamprecht

The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein

[object Object]

The present invention relates to novel compounds of formula (I) or a salt thereof: wherein Ris a 5-membered heteroaryl group, optionally fused with a 6-membered hetero or carbocycle; such 5 or 11-membered system, may be optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, Calkyl, haloCalkyl, Calkoxy, Calkanoyl, haloCalkoxy and SF; and n is 1 or 2; their use in therapy, as modulators of dopamine Dreceptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, or premature ejaculation.

Azabicyclo [3. 1. O] hexyl derivatives as modulators of dopamine D3 receptors

Compounds of formula (I) or a salt thereof are disclosed: wherein Ris pyrazolyl substituted by two or three substituents independently selected from halogen, Calkyl and haloCalkyl; Ris hydrogen or methyl; and Ris quinolinyl, oxazolyl or phenyl, each of which is optionally substituted by one or two halogen, Calkyl or haloCalkyl. Processes for preparation and uses of the compounds in medicine, for example for the treatment of schizophrenia or drug dependency, are also disclosed.

7-pyrazolylbenzazepines having affinity for D3 receptor

Compounds of formula (I) wherein A is a 5 or 6 membered heteroaromatic ring or a 5 or 6 membered heterocyclic ring, and which are useful for treating mental disorders such as schizophrenia are set out herein.

Compounds having affinity for dopamine D3 receptor and uses thereof

The present invention relates to novel compounds of formula (IC) or a salt thereof: wherein:

Triazolyl derivatives of azabicyclo [3.1.0] hexane as dopamine D3 receptor modulators

The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof: 

The present invention relates to novel compounds of formula (I)' or a salt thereof: wherein and the other groups are define in herein.

Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione

A compound of formula (I), salts and metabolically labile esters thereof, wherein R represents optionally substituted aryl or heteroaryl group; A represents a propylene chain or A is a chain of members one of which is selected from an oxygen or sulphur atom or the group NH or a substituted derivative thereof and the other two members are methylene groups, having antibacterial activity, processes for their preparation and to their use in medicine.

Tricyclic carbapenem compounds

Growing community of inventors

Verona, Italy

Giovanna Tedesco